Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer

RCT (n=616) reports improved overall survival (OS) with pemetrexed: at median follow-up of 23.1months, updated OS was 22.0months (95% CI 19.5 to 25.2) in pembrolizumab-combination group v 10.7months (8.7 to 13.6) in the placebo- group (HR 0.56; 95% CI, 0.45 to 0.70).


Journal of Clinical Oncology